These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22613863)

  • 1. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
    Schad K; Baumann Conzett K; Zipser MC; Enderlin V; Kamarashev J; French LE; Dummer R
    Clin Cancer Res; 2010 Feb; 16(3):1058-64. PubMed ID: 20103661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
    Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
    Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
    Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
    Reyes-Habito CM; Roh EK
    J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG; Mirvish ED; Geskin LJ
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
    Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
    Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
    Lacouture M; Sibaud V
    Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.
    Choi JN
    Clin Dermatol; 2011; 29(6):587-601. PubMed ID: 22014981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
    Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
    Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
    Curry JL; Torres-Cabala CA; Kim KB; Tetzlaff MT; Duvic M; Tsai KY; Hong DS; Prieto VG
    Int J Dermatol; 2014 Mar; 53(3):376-84. PubMed ID: 23879247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cutaneous toxicities].
    Matsumoto K; Saida T
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1645-8. PubMed ID: 18931563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.